Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01896921 · ClinicalTrials.gov registry record · Phase 3
Switch to Maraviroc + Integrase Inhibitor
A Phase 3 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT01896921 is a Phase 3 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 7 participants.
The verdict
NCT01896921, a Phase 3 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
This clinical study proposes to evaluate the combination of maraviroc with an integrase strand transfer inhibitor (either raltegravir or dolutegravir) in antiretroviral-experienced patients to document the efficacy, safety, and tolerability of this combination in order to provide clinicians with a treatment regimen that minimizes the risk of metabolic complications by avoidance of NRTI/NNRTIs and PIs. The development of an alternative ART regimen which lessens the risk of metabolic complications could improve long-term adherence and reduce the risk of certain co-morbidities associated with long-term ART use. If this new combination is found to be as efficacious as the standard regimen with enhanced tolerability and improved metabolic effects, there is great potential for altering the current practice of HIV medicine.
Interventions
- DRUG Switch to Maraviroc + Raltegravir or Dolutegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-09 |
| Est. Completion | 2018-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01896921
The ClinicalTrials.gov registry entry for NCT01896921 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Switch to Maraviroc + Raltegravir or Dolutegravir is the first listed.
NCT01896921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01896921 about?
NCT01896921 is a clinical study titled "Switch to Maraviroc + Integrase Inhibitor". This clinical study proposes to evaluate the combination of maraviroc with an integrase strand transfer inhibitor (either raltegravir or dolutegravir) in antiretroviral-experienced patients to document the efficacy, safety, and tolerability of this combination in order to provide clinicians with a t...
What is the current status of trial NCT01896921?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2013-09. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01896921?
The interventions under investigation include: Switch to Maraviroc + Raltegravir or Dolutegravir (DRUG).
Who is sponsoring clinical trial NCT01896921?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.